| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA730: Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) |
|
Medicine details |
|
| Medicine name | avapritinib (Ayvakyt®) |
| Formulation | Oral formulation |
| Reference number | 4256 |
| Indication | Monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation |
| Company | Blueprint Medicines |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/09/2020 |
| NICE guidance | |